EyeWorld Asia-Pacific March 2012 Issue

March 2012 25 EW FEATURE Only TECNIS ® Multifocal IOLs are individually shaped by a unique diamond cryolathe to ... AMO ENGINEER ... provide you with the confidence of delivering a predictable, high-quality ... OPHTHALMOLOGIST ... Wow ! TECNIS ® MULTIFOCAL IOL PATIENT THERE’S A REASON YOU’LL BE HEARING A LOT OF “WOWS!” FROM TECNIS ® MULTIFOCAL IOL PATIENTS. It goes beyond our pupil-independent lens design; it has to do with how each lens is made. Unlike other IOLs, each TECNIS ® Multifocal lens is individually diamond-cryolathed from a proven hydrophobic acrylic material not associated with glistenings. 1 The result is a lens delivering a predictable full range of high-quality outcomes for your patients. All distances. 2 All lighting. 2 All in 1-piece. TECNIS ® Multifocal intraocular lenses are indicated for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire near, intermediate and distance vision with increased spectacle independence. The intraocular lenses are intended to be placed in the capsular bag. 1. Miyata A, Yaguchi S. Equilibrium water content and glistenings in acrylic intraocular lenses. J Cataract Refract Surg. 2004;30:1768–1772. 2. Terwee T, Weeber H, van der Mooren M, Piers P. Visualization of the retinal image in an eye model with spherical and aspheric, diffractive and refractive multifocal intraocular lenses. J Refract Surg . 2008;24:223–232. TECNIS is a trademark owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. ©2012 Abbott Medical Optics Inc. www.AbbottMedicalOptics.com 2011.12.14-CT4391 light,” Dr. Rivera said. One initial complication with the KAMRA, back in the days when practitioners were still determining how to best implant this, included flap melts. In Dr. Waltz’s experience, however, patients have ultimately fared well. “Every patient who has had a flap melt sees fine afterward,” he said. “The most impressive thing about this technology is that everyone who has had complications is doing great, and there is not another technology that you can say that about.” Dr. Tomita sees dry eye as the most important complication. “Because we have to make a 200-micron flap for simultaneous LASIK, we have to cut a lot of corneal nerves and there will be dry eyes,” he said. Pre-op, he puts in a plug in cases of slight dry eye and in more serious instances offers Restasis (cyclosporine, Allergan, Irvine, Calif., USA) and artificial tears. In Dr. Rivera’s view the potential patient base is huge. Besides the traditional LASIK contingent, this is something for which the standard pseudophakic patients who underwent surgery possibly years ago can opt. “We’ll be able to restore their ability to read up close,” Dr. Rivera said. “It’s going to be something that we’ve never been able to offer them before, and I think that there’s going to be broad interest.” Currently, the data has been submitted to the FDA. “We’re hoping in the next year or year and a half that it will be approved,” Dr. Rivera said. Overall, Dr. Knorz is optimistic about the device. “I think that the KAMRA has the potential to replace monovision as the main tool of presbyopia correction in corneal surgery,” he said. “It’s much better and safer than any style of ‘presbyopia-correcting’ laser ablation.” EW Editors’ note: Dr. Knorz has financial interests with AcuFocus and Alcon (Fort Worth, Texas, USA/Hünenberg, Switzerland). Dr. Rivera has financial interests with AcuFocus. Dr. Tomita has financial interests with AcuFocus, Ziemer (Alton, Ill., USA), and Schwind (Kleinostheim, Germany). Dr. Waltz has financial interests with AcuFocus. Contact information Knorz: knorz@eyes.de Rivera: 801-568-0200, rpriveramd@aol.com Tomita: +81.3.5221.2207 , tomita@shinagawa.com Waltz: 317-841-2020, kwaltz@aol.com